PACE Technology

Clinical Studies

Scientific Literature

Products


SANUWAVE Health to Present at the Rodman & Renshaw Annual Global Investment Conference

SANUWAVE to Present Newest Device, Profile™, at the 20^th Biennial Congress of the International Society of Aesthetic Plastic Surgery

SANUWAVE Health Reports Second Quarter Financial Results and Provides Business Update

The dermaPACE device is currently available only to physicians and patients involved in an Investigational Device Exemption clinical trial. It is not for sale in the United States. For further information regarding dermaPACE please visit: www.dermaPACE.com or for more information on the trial please visit: www.ClinicalTrials.gov

The orthoPACE™ is CE marked for international markets for orthopedic and musculoskeletal indications, but is not currently approved for sale or distribution in the United States.

The OssaTron is the first and only Extracorporeal Shock Wave Technology (ESWT) system approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple orthopaedic conditions which have failed to respond to conservative treatment.